Pathogenesis of Ovarian Serous Carcinoma as the Basis for Immunologic Directed Diagnosis and Treatment. Project 2 - Identification of Autologous Antigens in Early Stage Serous Carcinoma
Abstract
Our goal is to develop an early detection screening test for serous carcinoma. Specific aim 1: Obtain cDNAs of autologous tumor antigens recognized by sera of patients with early stage serous carcinoma, but not controls. Progress: While our ovarian cancer cDNA library is construction for SEREX analysis, we have developed an alternative, complementary methodology. We employed patient sera to immunoprecipitate proteins from autologous cancer cells and identified these antigens by mass spectrometry. One antigen, SMAP-1, has homology to genes that facilitate cell division. Specific aim 2: Identify autologous tumor antigens expressed in serous carcinoma but absent from, or a low level in normal tissue. Progress: We have expressed recombinant SMAP-1 protein and generated specific antisera. We the SMAP-1 mRNA is ubiquitous in all tissues tested thus far, and immunohistochemical studies are currently underway. We have already several identified several other SEREX antigens, including the homeobox HOXB7 transcription factor. We have generated peptide antiserum to HOXB7 and confirmed its over expression in cancer cell lines. Interestingly, we also note a shift from a nuclear localization in normal tissue to the cytoplasm in most carcinomas.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2003
- Accession Number
- ADA420895
Entities
People
- Richard Roden
- Robert J. Kurman
Organizations
- Johns Hopkins University